Hayfin is pleased to announce that, through its Private Equity Solutions strategy, it is serving as lead investor in a €155 million Healthcare Continuation Vehicle established by Alantra Private Equity to support the next phase of growth of Health in Code.

Formed in 2020 through the merger of specialist genetic diagnostics companies, Health in Code has built an integrated clinical genomics platform serving healthcare providers in over 30 countries. Its offering spans next generation sequencing, diagnostic kits and its bioinformatics engine, supported by one of Europe’s most comprehensive variant databases.

Health in Code has grown at pace, driven by double-digit organic growth and through strategic add-ons to create a fully integrated player. Hayfin’s investment, alongside Mérieux Equity Partners acquiring a 20% equity stake in the platform, positions Health in Code well for continued growth and international expansion.

Gonzalo Erroz, Managing Director and Co-Head of Private Equity Solutions at Hayfin, commented: “We are pleased to partner with Alantra to support Health in Code at this pivotal stage of its evolution. As demand for advanced genetic diagnostics continues to accelerate, the Continuation Vehicle will provide Health in Code with the resources to broaden its footprint and continue delivering high quality, clinically impactful insights to Spanish hospitals.”

Ali Sangari, Director, Private Equity Solutions at Hayfin, commented: “This transaction underscores our experience of partnering with sponsors with whom we have long-standing relationships to back sector leading assets in the healthcare space. Health in Code has built a uniquely integrated genomics platform, and we are excited to back the team as they accelerate their next phase of growth.”